Research into hypochondroplasia and related FGFR3 skeletal dysplasias is moving quickly. There is currently no cure for hypochondroplasia. However, several companies and research groups are studying treatments that aim to improve growth, body proportions, function, mobility, or quality of life. Some treatments are already approved for achondroplasia but not hypochondroplasia.
Others remain investigational and are being studied in clinical trials. This page is intended to help families understand the current research landscape. It does not recommend or endorse any specific treatment, company, or clinical trial. Families considering participation in research should speak with their healthcare team and carefully review the purpose, eligibility criteria, risks, benefits, and practical commitments of any study.
Why research matters in hypochondroplasia
Hypochondroplasia remains under-recognised and under-studied compared with achondroplasia. Important research questions include:
Natural history studies, patient registries, clinical trials, and qualitative research all play an important role in building better understanding.
Current areas of treatment research
CNP pathway therapies
Some therapies aim to increase activity in the C-type natriuretic peptide, or CNP, pathway. This pathway can help counterbalance overactive FGFR3 signalling, which is involved in hypochondroplasia and achondroplasia. Examples include:
Vosoritide is approved for achondroplasia in some countries and is being studied in children with hypochondroplasia. Navepegritide, developed as TransCon CNP, is a once-weekly CNP prodrug approved in the United States for children with achondroplasia aged 2 years and older, but not currently approved for hypochondroplasia.
FGFR-targeted therapies
Other treatments aim to act more directly on FGFR signalling.
Examples include:
These approaches are at different stages of development. Some are being studied in achondroplasia, while others are moving into or being considered for hypochondroplasia and related skeletal dysplasias.
Companies and programmes to watch
BioMarin
BioMarin developed vosoritide, marketed as VOXZOGO® for achondroplasia in several countries. Vosoritide is designed to stimulate the CNP pathway and support bone growth. BioMarin is also studying vosoritide in children with hypochondroplasia, including interventional and observational studies.
Relevant links:
https://clinicaltrials.biomarin.com/areas-of-clinical-research/hypochondroplasia/
BridgeBio / QED Therapeutics
QED Therapeutics, part of BridgeBio, is studying infigratinib, an oral FGFR-targeted therapy. Infigratinib is being studied in achondroplasia and hypochondroplasia. BridgeBio has announced plans to accelerate development in hypochondroplasia following achondroplasia trial results.
Relevant links:https://clinicaltrials.gov/study/NCT06873035
Ascendis Pharma
Ascendis developed navepegritide, also known as TransCon CNP, a long-acting CNP prodrug designed for once-weekly administration. Navepegritide has been developed for achondroplasia. At present, it is not approved specifically for hypochondroplasia, but CNP-pathway research is relevant to the wider field of FGFR3-related skeletal dysplasias.
Relevant link:https://pmc.ncbi.nlm.nih.gov/articles/PMC12624480/
TYRA Biosciences
TYRA Biosciences is developing TYRA-300, an investigational oral FGFR3-selective inhibitor. TYRA-300 is being developed for skeletal dysplasias including achondroplasia, based on the role of FGFR3 signalling in bone growth.
Relevant link:https://pubmed.ncbi.nlm.nih.gov/39258897/
Sanofi
Sanofi has a programme involving SAR-442501, an investigational therapy targeting FGFR3. This programme is currently described in relation to achondroplasia and osteochondrodysplasia.
Relevant link: Link
Pfizer / Recifercept
Recifercept was an investigational therapy for achondroplasia designed to reduce FGFR3 signalling by acting as a decoy receptor. Pfizer discontinued development of recifercept in 2023, but it remains useful historically because it shows how the treatment landscape has evolved.
Relevant link: https://globalgenes.org/raredaily/pfizer-shelves-two-rare-disease-programs/
Innoskel
Innoskel is developing gene therapy approaches for rare skeletal disorders, particularly type II collagen disorders such as SEDC. This is not currently a hypochondroplasia-specific programme, but it is relevant to the wider rare bone disorder research landscape.
Relevant link: https://firstwordpharma.com/story/5463735
Abbisko Therapeutics
Abbisko is developing ABSK061, a selective FGFR2/3 inhibitor designed to target signalling pathways involved in skeletal dysplasias.
Link: https://www.abbisko.com/newsDetail/240.html
Ribomic
Ribomic is developing Umedaptanib Pegol (RBM-007), an anti-FGF2 RNA aptamer that works by inhibiting fibroblast growth factor 2 (FGF2), a pathway distinct from FGFR3 but relevant to bone growth regulation.
Active studies
Clinical trial information changes frequently. Families should always check the official study page and speak with their healthcare team before considering participation. Examples of current or recent hypochondroplasia-related studies include:
BioMarin: observational study in children with hypochondroplasia
This study is designed to assess growth over time and the clinical course of hypochondroplasia in children by collecting growth measurements and other variables of interest.
BioMarin: vosoritide versus placebo in children aged 0 to under 36 months
This study is evaluating the safety and efficacy of daily vosoritide in children with hypochondroplasia aged 0 to under 36 months.
Study link:https://clinicaltrials.gov/study/NCT07126262
BioMarin: vosoritide in children aged 3 to 17 years
This Phase 3 study is assessing vosoritide as a therapeutic option for children with hypochondroplasia aged 3 to 17 years. At the time of review, the study was listed as active, not recruiting.
Study link:https://clinicaltrials.gov/study/NCT06455059
BioMarin: long-term extension study of vosoritide
This long-term extension study is evaluating the safety and efficacy of daily vosoritide in participants with hypochondroplasia who have taken part in previous studies.
Study link:https://clinicaltrials.gov/study/NCT07073014
BridgeBio / QED: The ACCEL observational study: Diagnostic features, medical history, and baseline characteristics of children with hypochondroplasia
ACCEL is a global, prospective, observational study actively enrolling participants. Eligible children must be aged 2.5 to <17 years old with the potential to grow at study entry and have a clinically documented diagnosis of HCH confirmed by a molecular test. The measurements collected in ACCEL will lead to a better understanding of the growth, physical characteristics, thinking ability, and possible medical challenges that people with HCH can experience.
Study links:
https://clinicaltrials.gov/study/NCT06410976
https://bridgebio.com/science/hypochondroplasia/trials
https://www.sciencedirect.com/science/article/pii/S2949774426001159
List of actively recruiting clinical trials in the U.S,:
https://clinicaltrials.gov/search?cond=Hypochondroplasia&aggFilters=status:&viewType=Table
Copyright © 2026 Hypochondroplasia Foundation. Register Number: 819128 - Ireland - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.